Vanda Pharmaceuticals (VNDA) EBIT Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported EBIT Margin of 97.11% for Q1 2026, down 1512.0% on a YoY basis from 6.88% in Q1 2025, and down 37.69% sequentially from 70.53% in Q4 2025.
Vanda Pharmaceuticals (VNDA) EBIT Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of EBIT Margin data on file, last reported at 97.11% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 1512.0% year-over-year to 97.11%; the trailing twelve-month figure through Mar 2026 stood at 73.64% (down 3765.0% YoY), and the FY2025 full-year result was 69.95%, down 4950.0% from the prior year.
- EBIT Margin fell to 97.11% in Q1 2026, from 70.53% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 10.28% in Q4 2022 to a low of 97.11% in Q1 2026.
- A 5-year average of 28.57% and a median of 19.33% in 2024 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin surged 1595 bps in 2023 and sank 6253 bps in 2025, its largest moves.
- Tracing VNDA's EBIT Margin over 5 years: stood at 10.28% in 2022, then sank by 252 bps to 15.67% in 2023, then retreated by 23 bps to 19.33% in 2024, then slumped by 265 bps to 70.53% in 2025, then plunged by 38 bps to 97.11% in 2026.
- Business Quant data shows VNDA's EBIT Margin at 97.11% in Q1 2026, 70.53% in Q4 2025, and 55.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -97.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.11% |
| Dec 31, 2025 | -70.53% |
| Sep 30, 2025 | -55.61% |
| Jun 30, 2025 | -73.21% |
| Mar 31, 2025 | -81.99% |
| Dec 31, 2024 | -19.33% |
| Sep 30, 2024 | -23.08% |
| Jun 30, 2024 | -20.10% |
| Mar 31, 2024 | -19.46% |
| Dec 31, 2023 | -15.67% |
| Sep 30, 2023 | -15.45% |
| Jun 30, 2023 | -6.23% |
| Mar 31, 2023 | 3.21% |
| Dec 31, 2022 | 10.28% |
| Sep 30, 2022 | 5.98% |
| Jun 30, 2022 | 5.38% |
| Mar 31, 2022 | -12.74% |
| Dec 31, 2021 | 12.70% |
| Sep 30, 2021 | 15.43% |
| Jun 30, 2021 | 18.22% |